Company: ACBM
Filing Date: 2025-07-23
Form Type: 10-Q
Source: 0001640334-25-001279
Chunk: 16

Company: ACRO BIOMEDICAL CO., LTD.
Filing Date: 2025-07-23
Form: 10-Q
Item: Item 1
Chunk 16
---
 Net loss  -   -   -   -   -   -   (4,004,354)  (4,004,354)                                 Balance, March 31, 2023  -   -   60,042,000   60,042   32,296,024   (4,132,883)  (27,812,279)  410,904                                  Amortization of deferred stock compensation   -   -   -   -   -   3,123,450   -   3,123,450 Imputed interest on related party loans  -   -   -   -   789   -   -   789 Net loss  -   -   -   -   -   -   (3,195,489)  (3,195,489)                                 Balance, June 30, 2023  -  $-   60,042,000  $60,042  $32,296,813  $(1,009,433) $(31,007,768) $339,654 

The accompanying notes are an integral part of these unaudited financial statements.

 6Table of Contents

ACRO BIOMEDICAL CO., LTD.

Statements of Cash Flows

(Unaudited) 

   Six Months Ended     June 30,    2024  2023        CASH FLOWS FROM OPERATING ACTIVITIES      Net loss $(21,395) $(7,199,843)Adjustments to reconcile net loss to net cash used in operating activities:        Imputed interest - related parties  2,011   1,577 Amortization of deferred stock compensation   -   7,051,550 Changes in operating assets and liabilities:        Accounts receivable  -   140,000 Prepaid expenses  1,250   (7,565)Accounts payable and accrued expenses  (1,708)  10,965 Net cash used in operating activities  (19,842)  (3,316)         CASH FLOWS FROM